2型糖尿病における血糖制御,インスリン感受性,ベータ細胞機能に対するグルカゴンのようなペプチド1の6週間の効果:並列グループ研究
Mette Zander1, Sten Madsbad, Jan Lysgaard Madsen
1Department of Medical Physiology, Panum Institute, University of Copenhagen, Copenhagen, Denmark. M.Zander@dadlnet.dk
Lancet (London, England)
|March 19, 2002
まとめ
グルカゴン類ペプチド1 (GLP-1) の継続的な治療は,2型糖尿病患者の血糖コントロールとベータ細胞機能を著しく改善しました. この試験試験では,GLP-1が2型糖尿病の管理に有望な治療薬であることを示唆しています.
科学分野:
- エンドクリノロジー エンドクリノロジー
- メタボリック疾患
背景:
- グルカゴン類ペプチド1 (GLP-1) は,2型糖尿病の潜在的な治療薬である.
- 継続的なGLP-1投与の長期的な効果は,調査が必要です.
研究 の 目的:
- 2型糖尿病患者の6週間の連続した皮下GLP-1注入の効果を評価する.
- 血糖コントロール,ベータ細胞機能,インスリン感受性,その他の代謝パラメータに対するGLP-1の影響を評価する.
主な方法:
- 2型糖尿病患者20人を対象とした6週間のランダム化プラセボ対照試験.
- 患者は,GLP-1 (n=10) または塩素 (n=10) の連続した皮下注入を受けた.
- 評価には,血糖プロファイル,ベータ細胞機能検査,インスリン感受性測定,食欲評価が含まれていました.
主要な成果:
- GLP-1輸液は,プラズマグルコース,HbA1c,およびフルクトサミンレベルを大幅に低下させた.
- インスリン感受性およびベータ細胞機能の改善が観察されました.
- 自由脂肪酸の濃度が低下し,胃の排泄が抑制され,体重が減少し,食欲が減ったことがGLP-1治療で観察されました.
結論:
- 継続的なGLP-1投与は,2型糖尿病に対する有意な治療の可能性を示しています.
- GLP-1治療の長期的な有効性と安全性を調べるためにさらなる研究が必要である.
関連する概念動画
Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...


